Imatinib Stada (Imatinib)

Imatinib blocks the ATP‑binding pocket of BCR‑ABL, c‑KIT and PDGFR tyrosine kinases, locking them in an inactive state. This prevents downstream signaling that leads to uncontrolled cell growth, thereby inhibiting malignant cell proliferation.

The specific dose of Imatinib Stada is determined by the prescribing clinician based on the patient’s diagnosis, disease stage, body weight, renal and hepatic function, and other individual factors. Only a qualified health professional should set the regimen.

Safety data for imatinib in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by the treating physician in consultation with the patient.

To request Imatinib Stada, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Imatinib was the first BCR‑ABL inhibitor approved and remains a standard of care for CML and Ph+ ALL. Newer agents such as dasatinib or nilotinib may offer potency advantages or different side‑effect profiles, but choice depends on disease characteristics, prior therapy, and individual tolerance.

Imatinib Stada should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Do not store in areas with high humidity or extreme temperature fluctuations.

Imatinib Stada is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water and not chewed or crushed unless specifically instructed by a healthcare professional.

Serious risks include severe neutropenia, hepatotoxicity, cardiac failure, and rare events such as pulmonary hypertension or severe hemorrhage. Patients should be monitored regularly for blood counts, liver enzymes and cardiac function, and any concerning symptoms reported promptly.

Imatinib Stada is contraindicated in patients with known hypersensitivity to imatinib or any of its excipients. Caution is also advised for individuals with pre‑existing severe liver disease, uncontrolled cardiac conditions, or those taking strong CYP3A4 inhibitors without appropriate monitoring.